Discover Funding Opportunities

BWF's Innovation in Regulatory Science Awards provides up to $500,000 over five years to academic investigators developing new methodologies or innovative approaches in regulatory science that will ultimately inform the regulatory decisions the Food and Drug Administration (FDA) and others make. The program especially encourages applications from those seeking to advance regulatory science approaches that will expedite the realization of equitable clinical outcomes. Applicants must hold a faculty or adjunct faculty appointment at a non-profit institution in the U.S. or Canada, which may include degree-granting institutions, research institutes, and teaching hospitals affiliated with academic degree-granting institutions. The program seeks to support innovative methodologies that address critical gaps in regulatory science and improve the evidence base for regulatory decision-making across various domains including drug development, medical devices, and public health policy.

The Next Generation Pregnancy Initiative (NGPI) is BWF's flagship funding mechanism in reproductive sciences, building upon the original Preterm Birth Initiative that ran from 2009 to 2019. After convening a Pregnancy Think Tank in 2019, BWF broadened the program's scope to address the interrelatedness of pregnancy duration, fetal growth, and adverse pregnancy outcomes including preterm birth, preeclampsia, intrauterine growth restriction, stillbirth, and maternal medical complications. Following a strategic reassessment, the 2025-2026 cycle focuses on refined priority areas including underlying mechanisms of normal pregnancy, preeclampsia, preterm birth, and late term pregnancy loss (excluding projects on miscarriage at 10 weeks or less and infertility-related loss). The program especially welcomes applications focused on subtyping adverse pregnancy outcomes, investigating maternal-fetal interactions, and integrating animal models with clinical outcomes. This award targets projects that have a solid basis for expanded study and could leverage NGPI funds to build a stronger foundation of evidence, making them more competitive for larger grant mechanisms like R01. The program provides four years of funding and moved to an annual cycle to address limited funding mechanisms in reproductive sciences.

The PhRMA Foundation's Predoctoral Fellowship in Value Assessment-Health Outcomes Research (VA-HOR) is designed to support promising students (U.S. and non-U.S. citizens) during advanced stages of training and thesis research in value assessment and health outcomes research. The Foundation seeks research proposals that investigate challenges and potential solutions related to evaluating the delivery, safe use, effectiveness, and value (clinical, patient-centered, and economic) of medicines and other health care interventions. Research areas include clinical outcomes assessments, patient-reported outcomes, patient health preferences research, clinical and economic outcomes using real-world data, evaluation and outcomes assessments focused on health equity or unmet need, innovative methods for measuring and reporting novel value elements, development of innovative decision and communication tools, patient-centered value assessment frameworks, and empirical health policy research. Proposals must incorporate patient engagement at an appropriate level through active, meaningful, and collaborative interaction between patients and researchers. Applicants must be full-time, in-residence PhD candidates at accredited U.S. universities who have completed at least two years of coursework and are engaged in thesis research.